Insights into the reasons for discontinuation and changes in the durability of the first line cART over time in Icona (Italian cohort of naive antiretrovirals)

Objectives: Changing treatment strategies over the last 10 years raised the issue of how the first line-treatment discontinuations and their causes have modified according to year of starting cART. We described the time spent on the first-line cART according to the reason of discontinuation and the predictors of discontinuation within 1 year after starting.
Methods: Patients who started cART (>2 drugs) when naïve with ³1 year of follow up on therapy were included. Time to discontinuing ³ 1 drug within the first year of cART for any reason, toxicity, failure, compliance, simplification (as reported in the cohort database) was analyzed by Kaplan-Meier curve; predictors of discontinuation were studied by logistic regression according to demographics, immunovirological parameters, calendar year of starting cART and regimen.
Results: Over a median follow up of 21 months (IQR 19-23) 72% of the 2740 patients enrolled discontinued therapy. 36% of the patients who started therapy in 1997-1999, 29% in 2000-2002 and 24% in 2003-2006 discontinued due to toxicity (the most frequent reason in each period). At one year the probability of discontinuing was 36% for any reason, 24% for toxicity, 20% compliance, 3% simplification, 5% failure. Patients who started cART in 2003-2006 compared to those who started in 1997-1999 had lower risk of discontinuing due to any reason (AOR 0.1 95%CI 0.06-0.1 vs 1997-1999), failure (AOR 0.4, 95%CI 0.2-0.8 vs 1997-1999), toxicity (AOR 0.3 95%CI 0.2-0.5 vs 1997-1999) and compliance (AOR 0.5 95%CI 0.3-0.8) and higer risk due to simplification (AOR 3.7 95%CI 2.2-5.9). Female sex (AOR 1.2 95%CI 0.9-1.5), HCV coinfection (AOR 1.2 95%CI 1.0-1.5), regimen started (2NRTI/bPI AOR 0.6 95%CI 0.4-0.9 and 2NRTI/1NNRTI AOR 0.3 95%CI0.2-0.4 vs 2NRTI/sPI) were predictors of discontinuation for any reason.
Conclusions: Toxicity was the most frequent reason for discontinuation. cART regimens started more recently showed higher durability, efficacy and tolerability.

Cicconi P.1, Cozzi Lepri A.2, Andrea D.L.3, Andrea A.4, Antonella C.5, Mussini C.6, D'Arminio Monforte A.1, I.Co.N.A.
University of Milan